Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanctura Once-Daily NDA Touts “Landmark Tolerability”

This article was originally published in The Pink Sheet Daily

Executive Summary

Indevus will position the XR version of its incontinence therapy based on its low incidence of dry mouth.

You may also be interested in...

Sanctura XR NDA Filing On Target For Year-End

Indevus reports Phase III trial results confirming earlier data demonstrating the efficacy of the once-daily overactive bladder treatment.

P&G Joins Novartis’ Efforts To Market Overactive Bladder Treatment Enablex

Co-promotion agreement leaves the door open for P&G and Novartis to solicit FDA for approval of Enablex as OTC. Deal brings expanded sales force in a crowded market.

Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s

Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts